RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties

被引:9
|
作者
Ah-Pine, Franck [1 ]
Casas, Deborah [2 ]
Menei, Philippe [3 ]
Boisselier, Blandine [1 ,2 ]
Garcion, Emmanuel [2 ]
Rousseau, Audrey [1 ,2 ]
机构
[1] CHU Angers, Dept Pathol Cellulaire & Tissulaire, 4 Rue Larrey, F-49100 Angers, France
[2] Univ Angers, Univ Nantes, INSERM, CRCINA, 4 Rue Larrey, F-49100 Angers, France
[3] CHU Angers, Dept Neurochirurg, 4 Rue Larrey, F-49100 Angers, France
来源
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 01期
关键词
GENOMIC LANDSCAPE; REARRANGEMENTS; FGFR; EGFR;
D O I
10.1016/j.tranon.2020.100884
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma (GBM) is the most frequent and most aggressive form of glioma. It is characterized by marked genomic instability, which suggests that chromothripsis (CT) might be involved in GBM initiation. Recently, CT has emerged as an alternative mechanism of cancer development, involving massive chromosome rearrangements in a one-step catastrophic event. The aim of the study was to detect CT in GBM and identify novel gene fusions in CT regions. One hundred and seventy ION-wild-type GBM were screened for CT patterns using whole-genome single nucleotide polymorphism (SNP) arrays. RNA sequencing was performed in 52 GBM with CT features to identify gene fusions within CT regions. Forty tumors (40/52, 77%) harbored at least one gene fusion within CT regions. We identified 120 candidate gene fusions, 30 of which with potential oncogcnic activities. We validated 11 gene fusions, which involved the most recurrent fusion partners (EGFR, SEPT14, VOPP1 and CPM), by RT-PCR and Sanger sequencing. The occurrence of CT points to underlying gene fusions in IDH-wild-type GBM. CT provides exciting new research avenues in this highly aggressive cancer.
引用
收藏
页数:10
相关论文
共 4 条
  • [1] Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma
    Stasik, Sebastian
    Juratli, Tareq A.
    Petzold, Andreas
    Richter, Sven
    Zolal, Amir
    Schackert, Gabriele
    Dahl, Andreas
    Krex, Dietmar
    Thiede, Christian
    NEOPLASIA, 2020, 22 (12): : 800 - 808
  • [2] In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
    Hernandez, Ainhoa
    Munoz-Marmol, Ana Maria
    Esteve-Codina, Anna
    Alameda, Francesc
    Carrato, Cristina
    Pineda, Estela
    Arpi-Llucia, Oriol
    Martinez-Garcia, Maria
    Mallo, Mar
    Gut, Marta
    del Barco, Sonia
    Gallego, Oscar
    Dabad, Marc
    Mesia, Carlos
    Bellosillo, Beatriz
    Domenech, Marta
    Vidal, Noemi
    Aldecoa, Iban
    de la Iglesia, Nuria
    Balana, Carmen
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [3] RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions
    Klubickova, Natalie
    Agaimy, Abbas
    Hajkova, Veronika
    Ptakova, Nikola
    Grossmann, Petr
    Steiner, Petr
    Michal, Michal
    Michal, Michael
    VIRCHOWS ARCHIV, 2022, 481 (04) : 613 - 620
  • [4] Targeted RNA sequencing in diagnostically challenging head and neck carcinomas identifies novel MON2::STAT6, NFATC2::NUTM2B, POC5::RAF1, and NSD3::NCOA2 gene fusions
    Chu, Ying-Hsia
    Katabi, Nora
    Sukhadia, Purvil
    Mullaney, Kerry A.
    Zaidinski, Michael
    Cracchiolo, Jeniffer R.
    Xu, Bin
    Ghossein, Ronald A.
    Ho, Alan L.
    Dinapoli, Sara E.
    Ladanyi, Marc
    Dogan, Snjezana
    HISTOPATHOLOGY, 2025, 86 (05) : 728 - 741